Midtrimester abortion by dilatation and evacuation versus intra-amniotic instillation of prostaglandin F2 alpha: a randomized clinical trial.
To compare the safety and feasibility of midtrimester abortion by outpatient dilatation and evacuation (D-E) versus inpatient intra-amniotic instillation of prostaglandin F2 alpha (PGF2 alpha), we performed a randomized clinical trial with 100 subjects estimated to be 13 to 18 menstrual weeks pregnant. Subjects undergoing D-E abortion had significantly better compliance with the assigned treatment (100% vs. 88%, < 0.05) and less delay prior to abortion (mean 3.7 vs. 10.1 days, p < 0.001). Subjects receiving PGF2 alpha had a relative risk of sustaining a complication 5.7 times that of subjects undergoing D-E (95% confidence interval 2.1-15.3, p < 0.001). Subjects receiving PGF 2 alpha also had significantly higher rates of vomiting and diarrhea (p < 0.01). Midtrimester abortion by outpatient D-E appears to be more acceptable to women, faster, and safer than by instillation of PGF2 alpha.
D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D000650:Amnion; D002986:Clinical Trials as Topic; D004107:Dilatation and Curettage; D005260:Female; D005865:Gestational Age; D006801:Humans; D007795:Laminaria; D011183:Postoperative Complications / Q000628:therapy; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011460:Prostaglandins F / Q000008:administration & dosage* / Q000009:adverse effects; D011897:Random Allocation
D011460:Prostaglandins F